Quarterly Result20 May 2025, 11:11 pm
Zim Laboratories Ltd Reports Q4 & FY25 Earnings, Sees 3.2% YoY Growth in Total Operating Income
AI Summary
Zim Laboratories Ltd has reported its Q4 & FY25 earnings. The total operating income grew to INR 3,790 Mn, a 3.2% YoY increase, driven by sustained export momentum and high-value innovative product contributions. Export revenue stood at INR 3,125 Mn, contributing 82% to the total operating income. EBITDA increased to INR 495 Mn with a margin of 13.1%. However, PAT declined to INR 122 Mn due to increased finance and depreciation costs.
Key Highlights
- Total Operating Income grew by 3.2% YoY
- Export revenue stood at INR 3,125 Mn, contributing 82% to the TOI
- EBITDA increased to INR 495 Mn with a margin of 13.1%
- Revenue from New Innovative Products rose by 81.8% YoY
- Revenue from Oral Thin Films grew 41.8% YoY
- Secured 2 EU Marketing Authorizations for Dimethyl Fumarate and Azithromycin Oral Suspension